Sökning: WFRF:(Pais A.) > (2005-2009) > Aspirin and extende...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 08195naa a2201093 4500 | |
001 | oai:gup.ub.gu.se/77923 | |
003 | SwePub | |
008 | 240528s2008 | |||||||||||000 ||eng| | |
009 | oai:DiVA.org:oru-81162 | |
009 | oai:prod.swepub.kib.ki.se:117567180 | |
024 | 7 | a https://gup.ub.gu.se/publication/779232 URI |
024 | 7 | a https://doi.org/10.1056/NEJMoa08050022 DOI |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-811622 URI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1175671802 URI |
040 | a (SwePub)gud (SwePub)orud (SwePub)ki | |
041 | a eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Sacco, R. L.u Miller School of Medicine, University of Miami, Miami, United States; Miller School of Medicine, University of Miami, Miami, United States,McMaster University, Hamilton, ON, Canada4 aut |
245 | 1 0 | a Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke |
264 | 1 | a Boston :b Massachusetts medical society,c 2008 |
520 | a BACKGROUND: Recurrent stroke is a frequent, disabling event after ischemic stroke. This study compared the efficacy and safety of two antiplatelet regimens--aspirin plus extended-release dipyridamole (ASA-ERDP) versus clopidogrel. METHODS: In this double-blind, 2-by-2 factorial trial, we randomly assigned patients to receive 25 mg of aspirin plus 200 mg of extended-release dipyridamole twice daily or to receive 75 mg of clopidogrel daily. The primary outcome was first recurrence of stroke. The secondary outcome was a composite of stroke, myocardial infarction, or death from vascular causes. Sequential statistical testing of noninferiority (margin of 1.075), followed by superiority testing, was planned. RESULTS: A total of 20,332 patients were followed for a mean of 2.5 years. Recurrent stroke occurred in 916 patients (9.0%) receiving ASA-ERDP and in 898 patients (8.8%) receiving clopidogrel (hazard ratio, 1.01; 95% confidence interval [CI], 0.92 to 1.11). The secondary outcome occurred in 1333 patients (13.1%) in each group (hazard ratio for ASA-ERDP, 0.99; 95% CI, 0.92 to 1.07). There were more major hemorrhagic events among ASA-ERDP recipients (419 [4.1%]) than among clopidogrel recipients (365 [3.6%]) (hazard ratio, 1.15; 95% CI, 1.00 to 1.32), including intracranial hemorrhage (hazard ratio, 1.42; 95% CI, 1.11 to 1.83). The net risk of recurrent stroke or major hemorrhagic event was similar in the two groups (1194 ASA-ERDP recipients [11.7%], vs. 1156 clopidogrel recipients [11.4%]; hazard ratio, 1.03; 95% CI, 0.95 to 1.11). CONCLUSIONS: The trial did not meet the predefined criteria for noninferiority but showed similar rates of recurrent stroke with ASA-ERDP and with clopidogrel. There is no evidence that either of the two treatments was superior to the other in the prevention of recurrent stroke. (ClinicalTrials.gov number, NCT00153062.) | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Allmänmedicin0 (SwePub)302242 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex General Practice0 (SwePub)302242 hsv//eng |
653 | a Aged | |
653 | a Angiotensin-Converting Enzyme Inhibitors/therapeutic use | |
653 | a Aspirin/*administration & dosage/adverse effects | |
653 | a Benzimidazoles/therapeutic use | |
653 | a Benzoates/therapeutic use | |
653 | a Brain Ischemia/epidemiology/prevention & control | |
653 | a Delayed-Action Preparations | |
653 | a Dipyridamole/adverse effects/*therapeutic use | |
653 | a Double-Blind Method | |
653 | a Drug Therapy | |
653 | a Combination | |
653 | a Factor Analysis | |
653 | a Statistical | |
653 | a Female | |
653 | a Hemorrhage/chemically induced | |
653 | a Humans | |
653 | a Kaplan-Meiers Estimate | |
653 | a Male | |
653 | a Middle Aged | |
653 | a Myocardial Infarction/epidemiology | |
653 | a Platelet Aggregation Inhibitors/administration & dosage/adverse | |
653 | a effects/*therapeutic use | |
653 | a Proportional Hazards Models | |
653 | a Recurrence/prevention & control | |
653 | a Risk | |
653 | a Stroke/*drug therapy/epidemiology/prevention & control | |
653 | a Ticlopidine/adverse effects/*analogs & derivatives/therapeutic use | |
653 | a Vascular Diseases/mortality | |
700 | 1 | a Diener, H. C.u University of Duisberg-Essen, Essen, Germany4 aut |
700 | 1 | a Yusuf, S.u McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada4 aut |
700 | 1 | a Cotton, D.u Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, United States4 aut |
700 | 1 | a Ounpuu, S.u Boehringer Ingelheim, Burlington, ON, Canada4 aut |
700 | 1 | a Lawton, W. A.u Boehringer Ingelheim, Bracknell, United Kingdom4 aut |
700 | 1 | a Palesch, Y.u Medical University of Soudi Carolina, Charleston, United States4 aut |
700 | 1 | a Martin, R. H.u Medical University of Soudi Carolina, Charleston, United States,Boehringer Ingelheim, Stockholm, Sweden4 aut |
700 | 1 | a Albers, G. W.u Stanford University, Medical Center, Palo Alto, CA, United States4 aut |
700 | 1 | a Bath, P.u University of Nottingham, Nottingham, United Kingdom4 aut |
700 | 1 | a Bornstein, N.u Ichilov Medical Center, Tel Aviv, Israel4 aut |
700 | 1 | a Chan, B. P.u National University Hospital, Singapore, Singapore,St. Johns's Medical College, Bangalore, India4 aut |
700 | 1 | a Chen, S. T.u Chang Gung Memorial Hospital, Tapei, Taiwan4 aut |
700 | 1 | a Cunha, L.u Hospitais da Universidade de Coimbra, Coimbra, Portugal4 aut |
700 | 1 | a Dahlöf, Björn,d 1953u Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för akut och kardiovaskulär medicin,Institute of Medicine, Department of Emergeny and Cardiovascular Medicine,Sahlgrenska University Hospital-Östra, Göteborg, Sweden4 aut0 (Swepub:gu)xdahbj |
700 | 1 | a De Keyser, J.u University Medical Center Groningen, Groningen, Netherlands4 aut |
700 | 1 | a Donnan, G. A.u University of Melbourne, Heidelberg West, Australia4 aut |
700 | 1 | a Estol, C.u Neurological Center for Treatment and Research, Buenos Aires, Argentina4 aut |
700 | 1 | a Gorelick, P.u University of Illinois, Chicago, United States4 aut |
700 | 1 | a Gu, V.u Boehringer Ingelheim Shanghai Pharmaceuticals, Shanghai, China4 aut |
700 | 1 | a Hermansson, K.4 aut |
700 | 1 | a Hilbrich, L.u Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, United States4 aut |
700 | 1 | a Kaste, M.u Helsinki University, Central Hospital, Helsinki, Finland4 aut |
700 | 1 | a Lu, C.u Huashan Hospital, Shanghai, China4 aut |
700 | 1 | a Machnig, T.u Boehringer Ingelheim, Ingelheim, Germany4 aut |
700 | 1 | a Pais, P.4 aut |
700 | 1 | a Roberts, R.4 aut |
700 | 1 | a Skvortsova, V.u Russian State Medical University, Moscow, Russian Federation4 aut |
700 | 1 | a Teal, P.u University of British Columbia, Vancouver, Canada4 aut |
700 | 1 | a Toni, D.u University La Sapienza, Rome, Italy4 aut |
700 | 1 | a VanderMaelen, C.u Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, United States4 aut |
700 | 1 | a Voigt, T.u Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, United States4 aut |
700 | 1 | a Weber, M.u SUNY Downstate College of Medicine, New York, United States4 aut |
700 | 1 | a Yoon, B. W.u Seoul National University Hospital, Seoul, South Korea4 aut |
700 | 1 | a von Euler, Mia,d 1967- |
710 | 2 | a Miller School of Medicine, University of Miami, Miami, United States; Miller School of Medicine, University of Miami, Miami, United Statesb McMaster University, Hamilton, ON, Canada4 org |
773 | 0 | t New England Journal of Medicined Boston : Massachusetts medical societyg 359:12, s. 1238-51q 359:12<1238-51x 1533-4406x 0028-4793 |
856 | 4 | u https://doi.org/10.1056/NEJMoa0805002y Fulltext |
856 | 4 8 | u https://gup.ub.gu.se/publication/77923 |
856 | 4 8 | u https://doi.org/10.1056/NEJMoa0805002 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-81162 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:117567180 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy